Johnson & Johnson Study Shows Earlier Use of Prostate Cancer Drug Improves Outcomes
Johnson & Johnson reported late-stage clinical trial results showing that using its prostate cancer drug apalutamide in combination with hormone therapy before and after surgery improves outcomes for men with high-risk localized or locally advanced prostate cancer.
Tickers: $JNJ
Topics: apalutamide hormone therapy Johnson & Johnson prostate cancer